Much of the research into α-synuclein, the major component of Lewy bodies in Parkinson’s and other neurodegenerative diseases, focuses on its role in synaptic vesicles and membranes. But could other ...

More than a decade has passed since researchers led by Dennis Selkoe of Brigham and Women’s Hospital in Boston first reported that when α-synuclein has its druthers, it prefers the company of three ...

In a recent study published in the Proceedings of the National Academy of Sciences, researchers assessed the capability of two small molecules of disintegrating alpha-synuclein fibrils. Parkinson's ...

AbbVie is bowing out of the alpha-synuclein race. Having taken a drug candidate to the cusp of phase 2, AbbVie has terminated its collaboration with BioArctic, leaving a clutch of rivals such as ...

Aggregates of the protein alpha-synuclein spread in the brains of people with Parkinson's disease through a cellular waste-ejection process, suggests a new study. Aggregates of the protein ...

Amsterdam, NL, November 13, 2019 - Aggregates of the protein alpha-synuclein arising in the gut may play a key role in the development of Parkinson's disease (PD). Investigators are testing the ...

Research suggests that the Mediterranean diet and certain others can lower Parkinson's risk, while those high in ...

Lifestyle modifications, particularly increased physical activity, have a host of benefits. New research suggests they may ...

Alpha synuclein is a key drug target in Parkinson's Disease with the ability to aggregate into oligomers and fibrils. Research into α-synuclein has rapidly progressed in recent years with a lot of the ...

A toxic protein forms dynamic pores in the membranes of brain cells—and that may be the key to understanding how Parkinson's disease develops. This is the conclusion of a new study from Aarhus ...